Abstract
When they were first produced 2 decades ago, monoclonal antibodies were enthusiastically touted as “magic bullets” that would find wide application in medical therapeutics and diagnostics. But a variety of problems including severe immune reactions prevented them from living up to the early hype. A recent conference on monoclonals and cancer therapy suggests, however, that some of the difficulties are slowly being overcome.

This publication has 0 references indexed in Scilit: